20642 Federal Register / Vol. 63, No. 80 / Monday, April 27, 1998 / Notices

transgenic animal, collecting the milk,

and isolating the polypeptide therefrom.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–11113 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Use of Short WAP Promoter

in Mammary Tissue of Transgenic

Animals

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 08/246,259, filed

May 19, 1994, entitled ‘‘Transgenic

Animals Secreting Desired Proteins Into

Milk’’ to Genzyme Transgenics

Corporation, having a place of business

in Framingham, Massachusetts. The

patent rights in these inventions have

been assigned to the United States of

America.

The field of use will be the use of the

invention for the production in

transgenic animals of alpha interferon,

alpha-1 proteinase inhibitor,

angiogenin, antithrombin III, beta

interferon, calf intestine alkaline

phosphatase, cystic fibrosis

transmembrane regulator, Factor X,

glutamic acid decarboxylase, human

growth hormone, human serum

albumin, insulin, longer acting tissue

plasminogen activator, myelin basic

protein, pro-insulin, prolactin, tissue

plasminogen activator, soluble CD4 HIV

receptor, the recombinant monoclonal

antibody against Lewis Y antigen

designated BR96, and the monoclonal

antibody designated CTLA4 Ig.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before June

26, 1998 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Leopold J. Luberecki, Jr.,

J.D., Technology Licensing Specialist,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Box 13, Rockville, MD

20852–3804; Telephone (301) 496–7735,

ext. 223; Facsimile: (301) 402–0220. A

signed Confidential Disclosure

Agreement will be required to receive

copies of the patent application.

SUPPLEMENTARY INFORMATION: The patent

application claims a transgenic, nonhuman mammal containing a gene that

encodes a protein, the gene being under

the transcriptional control of a

mammalian milk protein promoter

which does not naturally control the

transcription of the gene, the DNA

sequence further including DNA

enabling secretion of the protein. The

promoter can be that of a milk serum

protein, which includes the whey acid

protein (WAP) or a casein protein. The

invention permits the production of a

desired protein in a living domesticated

mammal, which is capable not only of

producing the desired protein, but

preferably of passing on the ability to do

so to its female offspring. The present

invention specifically includes an

exogenous DNA sequence that has the 5’

2.6 kb promoter fragment of hte mouse

whey acid protein (WAP) gene.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–11114 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Spectroscopic Imaging

Device Employing Imaging Quality

Spectral Filters

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of an exclusive license to

practice the invention embodied in U.S.

Patent Number 5,377,003 and U.S.

Patent Application Number 08/996,497,

entitled ‘‘Spectroscopic Imaging Device

Employing Imaging Quality Spectral

Filters’’, to Spectral Dimensions, Inc.,

having a place of business in Boston,

Massachusetts. The patent rights in this

application have been assigned to the

United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7 and may be

limited to the field of use of veterinary

and human clinical diagnosis.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before June

26, 1998 will be considered.

ADDRESSES: Requests for a copy of this

patent application, inquiries, comments,

and other materials relating to the

contemplating license should be

directed to: John Fahner-Vihtelic, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: 301/

496–7735 ext. 270; Fax: 301/402–0220;

e-mail: jf36z@nih.gov. A signed

Confidentiality Agreement will be

required to review copies of the patent

application.
Federal Register / Vol. 63, No. 80 / Monday, April 27, 1998 / Notices 20643

SUPPLEMENTARY INFORMATION: The

present technology is a novel imaging

device and methodology which

integrates both light microscopy and

spectroscopy. This invention allows for

the cost-effective development of highresolution spatial, chemical, and

spectral images. It provides a rapid

means for examining and collecting

large format images from vibrational and

visible spectra in a three-dimensional

sample. It is superior to current

equipment because it has no moving

parts. This device may be used as a tool

for the characterization of polymers,

semiconductors, contamination studies,

analysis of diffusion and failure

mechanisms, and has potential as a

diagnostic tool of clinical analysis of

histologic materials.

The prospective exclusive license

may be granted unless, within 60 days

from the date of this published Notice,

NIH receives written evidence and

argument that establishes that the grant

of the license would not be consistent

with the requirements of 35 U.S.C. 209

and 37 CFR 404.7. Properly filed

competing applications for a license

filed in response to this notice will be

treated as objections to the

contemplated license.

Comments and objections submitted

in response to this notice will not be

made available for public inspection,

and, to the extent permitted by law, will

not be released under the Freedom of

Information Act, 5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–11111 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[CA–930–5410–00–B097; CACA 38636]

Conveyance of Mineral Interests in

California

AGENCY: Bureau of Land Management,

Interior.

ACTION: Notice of segregation.

SUMMARY: The private land described in

this notice, aggregating 5.00 acres, is

segregated and made unavailable for

filings under the general mining laws

and the mineral leasing laws to

determine its suitability for conveyance

of the reserved mineral interest

pursuant to section 209 of the Federal

Land Policy and Management Act of

October 21, 1976. The mineral interests

will be conveyed in whole or in part

upon favorable mineral examination.

The purpose is to allow consolidation of

surface and subsurface of minerals

ownership where there are no known

mineral values or in those instances

where the reservation interferes with or

precludes appropriate nonmineral

development and such development is a

more beneficial use of the land than the

mineral development.

FOR FURTHER INFORMATION CONTACT:

Kathy Gary, Bureau of Land

Management, California State Office,

2135 Butano Drive, Sacramento,

California 95825, (916) 978–4677.

Mount Diablo Meridian

T. 33 N., R. 9 W.,

Sec. 17, E1⁄2SE1⁄4NW1⁄4NW1⁄4.

County—Trinity

As Reservation—All coal and other minerals.

Upon publication of this Notice of

Segregation in the Federal Register as

provided in 43 CFR 2720.1–1(b), the

mineral interests owned by the United

States in the private lands covered by

the application shall be segregated to

the extent that they will not be subject

to appropriation under the mining and

mineral leasing laws. The segregative

effect of the application shall terminate

by publication of an opening order in

the Federal Register specifying the date

and time of opening; upon issuance of

a patent or other document of

conveyance to such mineral interest; or

two years from the date of publication

of this notice, whichever occurs first.

Dated: April 17, 1998.

David McIlnay,

Chief, Branch of Lands.

[FR Doc. 98–11063 Filed 4–24–98; 8:45 am]

BILLING CODE 4310–40–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY–985–0777–66; WY–142430]

Proposed Lease of Public Lands Under

the Recreation and Public Purposes

Act in Washakie County, Wyoming,

Bighorn Basin Resource Area

ACTION: Notice of realty action.

SUMMARY: The following public lands

near the community of Worland,

Washakie County, Wyoming, have been

examined and found suitable for

classification for lease under the

provisions of the Recreation and Public

Purposes Act, as amended (43 United

States Code 849 et seq.) The Washakie

County Fair Board proposes to use the

lands for an Olympic-style crosscountry horse track and associated

jumping facilities.

Sixth Principal Meridian

T. 48 N., R. 93 W.,

Sec. 8, S1⁄2SE1⁄4SE1⁄4NE1⁄4, NE1⁄4SE1⁄4.

Sec. 9, E1⁄2W1⁄2SW1⁄4NW1⁄4,

E1⁄2SW1⁄4NW1⁄4, NW1⁄4SW1⁄4,

NW1⁄4SW1⁄4SW1⁄4NW1⁄4,

W1⁄2NW1⁄4NW1⁄4SE1⁄4,

E1⁄2NE1⁄4NE1⁄4SW1⁄4.

Containing 127.5 acres more or less.

FOR FURTHER INFORMATION CONTACT:

Bureau of Land Management, Worland

District Office, Steven R. Till, Realty

Specialist, P.O. Box 119, Worland

Wyoming 82401–0119, or telephone

(307) 347–5100.

SUPPLEMENTARY INFORMATION: The lands

are not needed for federal purposes.

Lease of the lands would be consistent

with current BLM land use planning

and would be in the public interest.

The lease would be subject to the

following terms and conditions:

1. Provisions of the Recreation and

Public Purposes Act and to all

applicable regulations of the Secretary

of the Interior.

2. All valid existing rights (for

example, rights-of-way, permits and

leases). Detailed information concerning

this action is available for review at the

office of the Bureau of Land

Management, Worland District, 101 S.

23rd Street, Worland, Wyoming.

Upon publication of this notice in the

Federal Register, the lands will be

segregated from all other forms of

appropriation under the public land

laws, including the general mining laws,

except for lease under the Recreation

and Public Purposes Act and leasing

under the mineral leasing laws. For a

period of 45 days from the date of

publication of this notice in the Federal

Register, interested persons may submit

comments regarding the proposed

classification of the lands to the District

Manager, Worland District Office, P.O.

Box 119, Worland WY 82401–0119.

Classification Comments: Interested

parties may submit comments involving

the suitability of the land for a crosscountry horse track and associated

jumping facilities. Comments on the

classification are restricted to whether

the land is physically suited for the

proposal, whether the use will

maximize the future use or uses of the

land, whether the use is consistent with

local planning and zoning, or if the use

is consistent with state and federal

programs.

Application Comments: Interested

parties may submit comments regarding

the specific use proposed in the

application and plan of development,

whether the BLM followed proper